Welcome to our dedicated page for Sophia Genetics Sa SEC filings (Ticker: SOPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SOPHiA GENETICS SA (Nasdaq: SOPH) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. SOPHiA GENETICS files reports such as Form 20-F and Form 6-K with the U.S. Securities and Exchange Commission, offering detailed information on its financial condition, operations, and material announcements related to its AI-powered healthcare technology business.
Recent Form 6-K filings have included unaudited interim condensed consolidated financial statements, management’s discussion and analysis of financial condition and results of operations, and press releases covering quarterly results and business updates. These documents give investors insight into revenue trends, non-IFRS measures such as adjusted gross profit and adjusted EBITDA, geographic revenue breakdowns, and segment information that includes the SOPHiA DDM™ Platform and workflow equipment and services.
Through this page, users can review how SOPHiA GENETICS reports on topics such as platform usage, analysis volumes, regional performance, and capital structure. Filings may also reference warrant liabilities, credit agreements, and other financial instruments, along with discussions of constant currency revenue and other metrics used by management to evaluate performance.
Stock Titan enhances these filings with AI-powered summaries that explain key points in accessible language, helping readers understand complex sections of financial statements and management commentary. Users can quickly identify important themes in SOPHiA GENETICS’ 20-F annual reports, 6-K current reports, and other submissions, and then drill into the original documents for more detail.
In addition, this page offers convenient access to information relevant to governance and capital markets activity, such as exhibits attached to 6-Ks and references to registration statements. While SOPHiA GENETICS is not a U.S. domestic issuer and does not file Forms 10-K or 10-Q, its 20-F and 6-K filings serve a similar role for investors analyzing SOPH stock and the company’s AI-driven precision medicine platform.
SOPHiA GENETICS reported preliminary unaudited results showing fourth quarter 2025 revenue of at least $21 million, about 20% higher than a year earlier, with more than 105,000 SOPHiA DDM™ analyses, up 16% year-over-year. For full year 2025, revenue is expected to be about $77 million, roughly 18% growth, with over 391,000 analyses, a new company record.
For 2026, the company guides to full year revenue between $92 million and $94 million, implying about 20% to 22% growth, and an adjusted EBITDA loss between $29 million and $32 million. Results are preliminary and subject to completion of year-end closing and audit procedures.
The company also announced a leadership transition plan. Ross Muken, currently President and a long-time senior executive, will become CEO effective July 1, 2026, while co‑founder Jurgi Camblong is expected to move to the role of Executive Chairman, subject to election at the Annual General Meeting in June 2026. In addition, Kevin Puylaert will become Chief Sales Officer in January 2026.
A notice under Rule 144 reports a planned sale of 117,541 shares of common stock with an aggregate market value of $583,003.36. The shares relate to an issuer with 67,847,058 shares outstanding and are expected to be sold around 01/09/2026 on NASDAQ through Morgan Stanley Smith Barney LLC.
The securities to be sold consist of 25,500 founder shares acquired on 03/18/2021 and 92,041 shares received as restricted stock units on 01/18/2026. The notice also lists multiple prior 10b5-1 sales for JURGI CAMBLONG between 10/10/2025 and 01/08/2026, each showing the number of common shares sold and gross proceeds. By signing, the person for whose account the sale is made represents that they are not aware of any undisclosed material adverse information about the issuer.
Form 144 for SOPH reports a proposed sale of 30,000 shares of common stock with an aggregate market value of $144,000.00. The shares are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on or about 01/07/2026, and the stock is listed on NASDAQ, where 67,847,058 common shares are shown as outstanding.
The securities to be sold include 17,933 common shares acquired on 01/07/2026 via exercise of stock options for cash and 12,067 founder shares acquired on 03/18/2021. The filing also lists prior Rule 10b5-1 sales for JURGI CAMBLONG over the past three months, such as 16,948 common shares sold on 01/06/2026 for gross proceeds of
SOPH filed a Form 144 notice for a proposed sale of 3,866 common shares. The shares were acquired as restricted stock units on 10/02/2025 and are slated for sale on or about 10/03/2025 through Morgan Stanley Smith Barney LLC Executive Financial Services on the NASDAQ. The filing lists an aggregate market value of $17,281.02 for the proposed shares and notes 67,579,560 shares outstanding.
The notice also details recent Rule 10b5-1 sales over the past three months: 09/19/2025 (381 shares; $1,211.35), 08/19/2025 (380; $1,304.01), 07/23/2025 (66; $226.38), 07/21/2025 (381; $1,349.54), and 07/07/2025 (1,703; $5,155.49).
SOPHiA GENETICS SA insider notice shows a proposed sale of 13,486 common shares, with an aggregate market value of $60,282.42, scheduled for 10/03/2025 on NASDAQ. The securities were acquired as Restricted Stock Units on 10/02/2025 from the issuer and the planned broker is Morgan Stanley Smith Barney LLC.
Recent sales by the same beneficial owner under a Rule 10b5-1 plan are disclosed: five separate sales totaling 10,016 shares between 07/07/2025 and 09/19/2025, generating gross proceeds shown per trade. The filer attests there is no undisclosed material adverse information and references Rule 10b5-1 instruction language in the form.
SOPHiA GENETICS SA insider filing notifies a proposed sale of 6,160 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ with an approximate sale date of 10/03/2025 and an aggregate market value of $27,535.20. The shares were acquired as Restricted Stock Units from the issuer on 10/02/2025 and payment/settlement is shown as 10/02/2025. The filing also discloses recent 10b5-1 sales by Daan Guido Maria van Well totaling 4,996 shares sold on 07/07/2025, 07/21/2025, 07/23/2025, 08/19/2025, and 09/19/2025 with combined gross proceeds of $15,599.32. The notice includes the required representation that the seller is not aware of undisclosed material adverse information.
SOPHiA GENETICS SA (SOPH) filing a Form 144 notifies a proposed sale of 6,833 common shares with an aggregate market value of $30,543.51 to be sold approximately on 10/03/2025 on NASDAQ. The shares were acquired as Restricted Stock Units on 10/02/2025 from the issuer and payment was recorded on 10/02/2025. The filing shows the seller previously completed Rule 10b5-1 sales totaling 5,337 shares across five transactions from 07/07/2025 through 09/19/2025, generating gross proceeds shown per transaction. The Form 144 includes the seller's representation that no undisclosed material adverse information exists and conforms to Rule 144 disclosure requirements.
SOPHiA GENETICS SA (SOPH) filed a Form 144 disclosing a proposed sale of 83,558 common shares through Morgan Stanley Smith Barney with an aggregate market value of $345,094.54 and an approximate sale date of 09/29/2025. The filing shows acquisition details: 42,729 shares as founders' shares acquired 03/18/2011 and 40,829 shares from restricted stock units dated 10/02/2025. The filer also reported multiple recent Rule 10b5-1 sales and an individual sale totaling 40,829 shares on 08/19/2025 with gross proceeds of $142,493.21. The notice includes the required representation regarding absence of undisclosed material information.
SOPHiA GENETICS SA (SOPH) Form 144 notice discloses a proposed sale of 10,415 common shares through Morgan Stanley Smith Barney on 09/26/2025 with an aggregate market value of $35,723.45. The shares were acquired as founders' shares on 03/18/2011. The filing also lists multiple recent dispositions by the same person, including several 10b5-1 plan sales and one direct sale of 40,829 shares on 08/19/2025. Total shares reported sold in the past three months sum to 83,725 shares. The filer affirms no undisclosed material adverse information and references compliance with Rule 10b5-1 where applicable.